DDA (Nepal)

The Nepal Department of Drug Administration (DDA — औषधि व्यवस्था विभाग) operating under the Ministry of Health and Population (MoHP) is the Federal Democratic Republic of Nepal's national regulatory authority for human + veterinary medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + traditional + complementary medicines (Ayurveda + Unani + Homeopathic + Amchi/Sowa-Rigpa + Naturopathy) + pharmacy practice + controlled substances + clinical trials. The DDA operates under the Drugs Act 2035 (1978) + Drugs Regulation 2043 + Drug Standard Regulation 2043 + Drug Inquiry & Inspection Regulation 2040 + Drug Registration Regulation 2038 + Nepal Pharmacy Council Act 2057 (2000) + Narcotic Drugs Control Act 2033 + DDA Director General Orders + DDA Circulars + DDA Guidelines.

DDA organisational structure includes:

• Minister of Health and Population — political head; appointed by Prime Minister.
• Secretary, MoHP — administrative head.
• Director General, DDA — DDA chief executive.
• Directors (Administration, Drug Registration, Drug Inspection, Drug Quality Control, Pharmacovigilance) — operational directors.
• Drug Registration Section — drug + biological + vaccine + generic + traditional-medicine registration.
• Drug Inspection & Inquiry Section — GMP + GDP + GPP inspections of Nepalese + foreign manufacturing facilities.
• Pharmacy Practice + Licensing Section — pharmacy + pharmaceutical-establishment licensing in coordination with Nepal Pharmacy Council.
• Medical Devices + Cosmetics Section — medical-device + IVD + cosmetic registration.
• Controlled Substances + Narcotics Section — narcotics + psychotropics framework coordination with Home Ministry + Narcotic Drugs Control Law Enforcement Unit + Nepal Customs.
• National Pharmacovigilance Centre — WHO PIDM affiliated national pharmacovigilance hub.
• Clinical Trials + Bioequivalence Section — CTA + Ethics Committee + IRB coordination with Nepal Health Research Council (NHRC).
• National Medicines Laboratory (NML) Kathmandu — pharmaceutical + biological + diagnostic testing capacity pursuing ISO/IEC 17025 + WHO PQ-Lab status.
• International Affairs Section — WHO + SAARC + bilateral coordination.
• Regional Drug Administration Offices — Biratnagar (Eastern) + Pokhara (Western) + Nepalgunj (Mid-Western) + Dipayal (Far-Western) regional offices providing substantial national coverage.
• Nepal Pharmacy Council (NPC) — statutory body under Pharmacy Council Act 2057 (2000) regulating pharmacist + pharmacy-assistant licensure + pharmacy education.

Nepal's distinctive mountainous + landlocked + post-earthquake-reconstruction operational context: Nepal operates within one of South Asia's most operationally challenging pharmaceutical-distribution environments, characterised by extreme mountain geography (8 of world's 14 highest peaks including Mount Everest) + landlocked status (reliant on Indian + Chinese transit routes) + substantial post-2015 Gorkha earthquake reconstruction + substantial federal-restructuring transition (2015 Constitution establishing 7 Provinces + 77 Districts + 753 Local Levels with concurrent health-jurisdiction). Nepal's pharmaceutical supply chain is dominated by Indian + Chinese + Bangladeshi + Pakistani pharmaceutical-import dependency reaching ~60-70% of domestic consumption, with emerging Nepalese-domestic manufacturing capacity covering ~30-40% of essential-medicines portion via ~50+ Nepalese-domestic manufacturers notably Lomus Pharmaceuticals + National Healthcare + Time Pharmaceuticals + Nepal Pharmaceuticals Laboratory + Quest Pharmaceuticals + Asian Pharmaceuticals + Deurali-Janta Pharmaceuticals + Curex Pharmaceuticals + Singha Durbar Vaidyakhana (state Ayurvedic manufacturer with substantial historical heritage since 1894) + Nepal Pharma Industries.

DDA is distinct from + complementary to: the Nepal Pharmacy Council (NPC — statutory body regulating pharmacist licensure + pharmacy education); the Nepal Medical Council (NMC — physician + dental licensing); the Nepal Health Research Council (NHRC — ethics committee + clinical-research coordination); the Association of Pharmaceutical Producers of Nepal (APPON — representing manufacturers); Department of Ayurveda + Alternative Medicine (DoAA — coordinating traditional Ayurvedic + Unani + Amchi/Sowa-Rigpa + Naturopathy framework); Home Ministry + Narcotic Drugs Control Law Enforcement Unit (substantial narcotics enforcement); Nepal Customs (import-export control); 7 Provincial Health Directorates + 77 District Health Offices (provincial drug inspection + enforcement under federal restructuring); academic-medical-centre clinical-research hubs (Tribhuvan University Institute of Medicine + B.P. Koirala Institute of Health Sciences + Kathmandu University + Patan Academy of Health Sciences + Nepal Army Institute of Health Sciences). Nepal's pharmaceutical environment is uniquely characterised by: substantial Indian + Chinese + Bangladeshi + Pakistani pharmaceutical-import dependency ~60-70%; emerging Nepalese-domestic manufacturing capacity ~30-40%; WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) operational space; substantial WHO PQ + UNICEF + Gavi-supported vaccine procurement; Nepali + English overlay labelling + Devanagari script; substantial Climate Zone IVa Indo-Gangetic Plain (Terai) + Climate Zone II temperate mid-hills + Climate Zone I cold Himalayan high-altitude stability requirements; substantial post-2015 earthquake reconstruction operational context; substantial federal-restructuring transition + concurrent provincial health-jurisdiction.

DDA is a WHO PIDM Member + WHO SEARO Member + SAARC Founding Member + ICH Observer + IGBA Member + WHO PQ programme participant + WTO TRIPS LDC pharmaceutical-patent waiver beneficiary + maintains substantial bilateral cooperation with Indian CDSCO + Bangladeshi DGDA + Pakistani DRAP + Sri Lankan NMRA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH + Chinese NMPA + Tibet Autonomous Region + UK MHRA + EU EMA + US FDA + Japanese PMDA + Korean MFDS + Thai FDA + Australian TGA + GCC GHC.

Nepalese pharmaceutical regulation operates under a layered framework of Acts + Regulations + DDA Director General Orders + DDA Circulars + DDA Guidelines — substantively incorporating WHO + ICH + PIC/S GMP + EU GMP + WHO TRS Annex elements:

• Drugs Act 2035 (1978) — foundational pharmaceutical law (modernisation pending).
• Drugs Regulation 2043 — operational regulations under Drugs Act 2035.
• Drug Standard Regulation 2043 — pharmaceutical-standard framework.
• Drug Inquiry & Inspection Regulation 2040 — inspection + enforcement framework.
• Drug Registration Regulation 2038 — drug + biological + vaccine + generic + traditional-medicine registration framework.
• Drug Consultative Council & Drug Advisory Committee Rules — advisory body governance framework.
• Nepal Pharmacy Council Act 2057 (2000) — pharmacist + pharmacy-assistant licensure framework.
• Narcotic Drugs Control Act 2033 — narcotics + psychotropics framework coordinated with Home Ministry + Narcotic Drugs Control Law Enforcement Unit.
• Nepal National Drug Policy — strategic pharmaceutical policy framework + Essential Drugs List + National Formulary.
• DDA Drug Registration Guidelines — substantive drug registration framework.
• DDA Medical Device Guidelines — substantively incorporating WHO + IMDRF + EU MDR + IVDR elements.
• DDA Cosmetics Guidelines — substantively incorporating EU Cosmetics Regulation elements.
• DDA GMP Guide — substantively aligned with WHO TRS 986 Annex 2 + PIC/S GMP + EU GMP elements.
• DDA GDP Guide — substantively aligned with WHO GDP + EU GDP elements including substantial high-altitude Himalayan cold-chain + earthquake-resilience considerations.
• DDA GCP Guide — substantively aligned with ICH E6(R2) + WHO GCP guidance + Nepal Health Research Council (NHRC) ethical-review framework.
• DDA GVP Guide — substantively aligned with WHO PV guidance + ICH E2 + EU GVP elements.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + International Pharmacopoeia + Indian Pharmacopoeia + Nepalese National Formulary.
• Nepal National Essential Medicines List + Nepalese National Formulary — substantively aligned with WHO Essential Medicines List.
• WHO TRIPS LDC Pharmaceutical Patent Waiver Operational Framework — substantial generic-manufacturing operational space (extended through 2034) allowing Nepalese manufacturers to manufacture + export generic versions of patented medicines before patent expiry in non-LDC jurisdictions.
• Variations + Registration Renewal framework.
• High-altitude Himalayan stability + earthquake-resilience operational framework — substantial post-2015 Gorkha earthquake reconstruction context affecting pharmaceutical-distribution infrastructure + cold-chain resilience requirements.

DDA operates the National Medicines Laboratory (NML) Kathmandu — pharmaceutical + biological + diagnostic testing capacity pursuing ISO/IEC 17025 + WHO PQ-Lab status via WHO + bilateral-donor capacity expansion. The DDA Drug Inspection & Inquiry Section conducts GMP + GDP + GPP inspections of ~50+ Nepalese-domestic manufacturing facilities + foreign manufacturing facilities for imported drug registration.

• ISO/IEC 17025 — NML pursuing ISO/IEC 17025 accreditation via WHO + bilateral-donor capacity expansion.
• WHO PQ-Lab — NML pursuing WHO PQ-Lab status via WHO + bilateral-donor capacity expansion.
• Vaccine cold-chain QC — substantial cold-chain capacity for Nepal National Immunization Programme (NIP) via WHO + UNICEF + Gavi-supported infrastructure with substantial high-altitude Himalayan cold-chain logistics challenges.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Counterfeit-medicine forensics — substantial forensic analytical support for DDA enforcement + Nepal Customs + Home Ministry + WHO Global Surveillance & Monitoring System contributions; substantial cross-border Indian + Chinese pharmaceutical-trade quality monitoring.
• High-altitude Himalayan + earthquake-resilience QC — substantial stability + quality monitoring under Climate Zone IVa Terai + Climate Zone II mid-hills + Climate Zone I Himalayan high-altitude conditions + post-earthquake distribution-infrastructure resilience.
• GMP Inspectorate — DDA Drug Inspection & Inquiry Section capability for Nepalese-domestic manufacturing facility GMP inspections + foreign manufacturing facility inspections for imported drug registration.
• Nepalese domestic manufacturer support — supports emerging Nepalese-domestic pharmaceutical-manufacturing industry covering ~30-40% of essential-medicines consumption notably Lomus Pharmaceuticals + National Healthcare + Time Pharmaceuticals + Nepal Pharmaceuticals Laboratory + Quest Pharmaceuticals + Asian Pharmaceuticals + Deurali-Janta Pharmaceuticals + Curex Pharmaceuticals + Singha Durbar Vaidyakhana + Nepal Pharma Industries.

DDA medical-device + IVD regulation operates under DDA Medical Device Guidelines substantively incorporating WHO + IMDRF + EU MDR + IVDR + GHTF elements. Nepal has minimal domestic medical-device-manufacturing capacity with substantial Indian + Chinese + Pakistani + Turkish + European + US medical-device-import dependency.

• Risk-based Classification — substantively aligned with WHO + IMDRF + EU MDR + IVDR + GHTF model.
• Nepalese Authorised Representative — Nepal-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + DDA regulatory interface.
• ISO 13485:2016 — recognised by DDA as QMS evidence framework.
• Reliance pathways — DDA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + WHO PQ + Indian CDSCO + Bangladeshi DGDA + Pakistani DRAP approval evidence as supporting evidence.
• Post-market vigilance — DDA operates medical-device adverse-event reporting; reporting timelines substantively aligned with WHO + IMDRF Adverse Event Reporting Codes.
• IVD Reactivigilance — DDA operates IVD reactivigilance reflecting Nepal's emerging clinical-laboratory infrastructure + substantial Tribhuvan University Institute of Medicine + B.P. Koirala Institute of Health Sciences + Patan Academy of Health Sciences research-laboratory capacity.
• Cosmetic Notification — cosmetics require DDA Cosmetic Notification + Nepali/English labelling + Devanagari script; INCI-aligned ingredient listing + safety substantiation.
• Traditional + Complementary Medicines — distinctive Nepalese-traditional Ayurveda + Unani + Amchi/Sowa-Rigpa + Naturopathy framework coordinated with Department of Ayurveda + Alternative Medicine (DoAA) recognising substantial Nepalese + South Asian + Tibetan/Himalayan traditional-medicine heritage including substantial Vaidya + Hakim + Amchi (Sowa-Rigpa) + Naturopath practitioner cadre; substantial Singha Durbar Vaidyakhana (state Ayurvedic manufacturer since 1894) heritage; substantial cross-border traditional Tibetan/Amchi medicine cooperation with Tibet Autonomous Region.
• High-altitude + earthquake-resilience medical-device considerations — substantial mountain-rescue + emergency-medical-device + earthquake-response medical-device operational considerations.

DDA operates the National Pharmacovigilance Centre coordinated by DDA's Pharmacovigilance Section. Nepal is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The National Pharmacovigilance Centre coordinates with 7 Provincial Health Directorates + 77 District Health Offices + healthcare-delivery facilities + Marketing Authorisation Holders. Nepalese pharmacovigilance is uniquely shaped by substantial vaccine surveillance commitments (Nepal National Immunization Programme + Gavi-supported campaigns) + substantial counterfeit-medicine quality-risk monitoring + substantial cross-border Indian + Chinese pharmaceutical-trade quality monitoring + substantial mountain-geography access constraints affecting PV data collection.

• National Pharmacovigilance Centre — coordinated by DDA Pharmacovigilance Section.
• WHO PIDM Member — Nepal contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Nepal PV Network — coordinated national network with effector centres in 7 Provincial Health Directorates + 77 District Health Offices + healthcare-delivery facilities + Marketing Authorisation Holders.
• ADR Reporting — DDA operates ADR reporting via National Pharmacovigilance Centre; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DDA accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with ICH E2 + WHO PV guidance.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
• Risk Management Plans (RMP) — DDA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — National Pharmacovigilance Centre operates active-surveillance programmes for COVID-19 vaccines + childhood immunisation + high-risk products with substantial mountain-geography access challenges.
• AEFI Surveillance — Nepalese vaccine adverse-event surveillance aligned with WHO methodology; substantial to Nepal National Immunization Programme + UNICEF + Gavi-supported immunisation campaigns.
• Matériovigilance + Cosmétovigilance — DDA operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — substantial cross-border Indian + Chinese pharmaceutical-trade quality monitoring including Rasuwagadhi/Kerung + Tatopani/Zhangmu + Birgunj/Raxaul + Bhairahawa/Sunauli + Kakarbhitta/Panitanki border crossings.

• WHO PIDM Member — Nepal contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• WHO PQ Programme Participant — substantial WHO PQ-listed product reliance for UNICEF + Gavi + WHO-supported procurement in Nepal.
• WHO SEARO Member — substantial WHO South-East Asia Regional Office cooperation reflecting Nepal's South Asian regional position.
• SAARC Founding Member — South Asian Association for Regional Cooperation (8 Member States) with SAARC Secretariat headquartered in Kathmandu providing substantial host-country regulatory cooperation role.
• ICH Observer — substantial ICH guideline implementation in Nepalese regulatory practice.
• IGBA Member — International Generic and Biosimilar medicines Association reflecting emerging Nepalese-manufacturer generic-industry participation.
• WTO TRIPS LDC Pharmaceutical Patent Waiver Beneficiary — substantial WTO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) providing substantial generic-manufacturing operational space.
• Indian CDSCO Bilateral — dominant South Asian + SAARC peer + cross-border pharmaceutical-trade dependency reaching ~50-60% of Nepalese pharmaceutical imports; substantial open-border + Indo-Nepal Treaty of Peace and Friendship 1950 framework.
• Bangladeshi DGDA Bilateral — substantial SAARC peer + Bangladeshi pharmaceutical-import partner.
• Pakistani DRAP Bilateral — substantial SAARC peer + Pakistani pharmaceutical-import partner + halal-pharmaceutical cooperation.
• Sri Lankan NMRA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH Bilateral — substantial SAARC peer cooperation.
• Chinese NMPA Bilateral — Belt and Road operational engagement + substantial cross-border pharmaceutical-trade via Rasuwagadhi/Kerung + Tatopani/Zhangmu border crossings.
• Tibet Autonomous Region — substantial cross-border traditional Tibetan/Amchi (Sowa-Rigpa) medicine cooperation reflecting substantial Himalayan traditional-medicine heritage.
• UK MHRA + EU EMA + US FDA Bilateral — substantial historical Commonwealth + Gurkha-veteran healthcare connection + export-market regulator cooperation.
• Japanese PMDA + Korean MFDS + Thai FDA + Australian TGA Bilateral — substantial bilateral-donor + export-market regulator cooperation.
• GCC GHC Bilateral — substantial Nepalese migrant-worker healthcare context (~3-5 million Nepalese migrant workers in GCC); substantial GCC-Nepal healthcare cooperation.
• Nepal Health Research Council (NHRC) — substantial national ethics committee + clinical-research coordination + WHO + bilateral-donor research cooperation.

• Drugs Act 2035 (1978) modernisation pending — substantial regulatory-framework modernisation pending; foreign manufacturers frequently under-anticipate transitional regulatory uncertainty.
• WHO TRIPS LDC pharmaceutical-patent waiver operational space under-leveraged — most operationally significant feature of Nepalese pharmaceutical market access; substantial WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) generic-manufacturing operational space frequently under-leveraged by foreign-licensor + Nepalese-manufacturer joint-venture + technology-transfer opportunities.
• Nepalese Authorised Representative not properly designated — application rejected at DDA intake or post-approval compliance failure; Nepalese Authorised Representative must be Nepal-resident legal entity with appropriate licensure.
• Nepali + English labelling deficiencies — Nepali + English required + Devanagari script; many applicants provide insufficient Nepali language patient leaflet content.
• DDA GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Nepalese-specific DDA GMP clarifications.
• Nepalese climate-zone stability data missing — Nepal spans Climate Zone IVa Terai + Climate Zone II mid-hills + Climate Zone I Himalayan high-altitude (above 2500m); requires substantial zonal-specific stability data including high-altitude considerations.
• WHO PQ programme reliance under-utilised — substantial WHO PQ-approved-product reliance pathway substantially accelerating DDA review frequently under-utilised.
• SRA reliance under-utilised — substantial EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS reliance pathway frequently under-utilised.
• SAARC peer reliance under-utilised — substantial Indian CDSCO + Bangladeshi DGDA + Pakistani DRAP peer reliance pathway reflecting South Asian + SAARC operational reality + dominant Indian pharmaceutical-import position frequently under-utilised.
• Bioequivalence centres + biowaiver — DDA BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice; substantial bioequivalence-centre capacity limitations in Nepal.
• Post-2015 earthquake reconstruction context under-anticipated — substantial post-2015 Gorkha earthquake reconstruction + ongoing earthquake-resilience requirements for pharmaceutical-distribution infrastructure + cold-chain frequently under-anticipated.
• Federal-restructuring transition complexity under-anticipated — substantial 2015 Constitution federal restructuring (7 Provinces + 77 Districts + 753 Local Levels) with concurrent provincial + local health-jurisdiction frequently under-anticipated by foreign manufacturers.
• Cross-border Indian + Chinese pharmaceutical-trade complexity under-anticipated — substantial open Indo-Nepal border + Rasuwagadhi + Tatopani + Birgunj + Bhairahawa + Kakarbhitta border-crossing complexity frequently under-anticipated.
• Substantial Nepalese-domestic manufacturer joint-venture not leveraged — emerging ~50+ Nepalese-domestic manufacturers + WHO TRIPS LDC pharmaceutical-patent waiver operational space substantially under-leveraged.
• Substantial Nepalese academic-medical-centre clinical-research capacity not leveraged — substantial Tribhuvan University Institute of Medicine + B.P. Koirala Institute of Health Sciences + Kathmandu University + Patan Academy of Health Sciences clinical-research capacity substantially under-leveraged.
• Variations strategy not planned — variations procedure with Nepalese-specific timelines + fee structure.
• Registration renewal timing missed — 5-year registration renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.
• SAARC Secretariat host-country opportunities not leveraged — substantial SAARC Secretariat headquartered in Kathmandu providing substantial regional regulatory cooperation opportunities frequently under-leveraged.
• GCC migrant-worker healthcare context not leveraged — substantial ~3-5 million Nepalese migrant workers in GCC providing substantial GCC-Nepal pharmaceutical-trade + healthcare-portability opportunities frequently under-leveraged.

V5 Ultimate provides the operational infrastructure Nepalese + foreign-supplier sites need for the Drugs Act 2035 (1978) + Drugs Regulation 2043 + DDA Drug Registration + DDA GMP + DDA Medical Device Guidelines + DDA Cosmetics Guidelines + WHO PQ programme participation + WHO TRIPS LDC pharmaceutical-patent waiver operational space + SAARC + WHO SEARO regional cooperation + National Pharmacovigilance Centre + substantial mountain-geography + earthquake-resilience + federal-restructuring operational context.

• DDA GMP control framework — WHO TRS 986 Annex 2 + PIC/S + EU GMP elements-aligned controls with ALCOA+ data-integrity + Nepalese-specific clarifications + Climate Zone IVa Terai + Climate Zone II mid-hills + Climate Zone I Himalayan high-altitude stability monitoring.
• DDA registration dossier packaging — Nepalese CTD-aligned dossier structure with Nepalese Module 1 specifics + Module 3 stability + Nepali/English patient leaflet + Devanagari script + Nepalese Authorised Representative declarations + substantial EU Module reuse.
• WHO TRIPS LDC pharmaceutical-patent waiver workflow — most operationally significant feature; substantial WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) generic-manufacturing operational space packaging including foreign-licensor + Nepalese-manufacturer joint-venture + technology-transfer opportunities support.
• WHO PQ programme reliance workflow — substantial WHO PQ-approved-product reliance pathway packaging.
• SRA reliance workflow — DDA-EMA + DDA-FDA + DDA-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging.
• SAARC peer reliance workflow (Indian CDSCO / Bangladeshi DGDA / Pakistani DRAP / Sri Lankan NMRA / Bhutanese DRA / Maldivian MFDA / Afghanistan MoPH) — substantial SAARC peer reliance packaging reflecting SAARC Secretariat host-country position.
• Nepalese Authorised Representative workflow — foreign-manufacturer Nepalese Authorised Representative designation + role-management + Nepal-specific post-market surveillance.
• Nepalese clinical-trial workflow — DDA CTA + Tribhuvan University Institute of Medicine + B.P. Koirala Institute of Health Sciences + Kathmandu University + Patan Academy of Health Sciences + Nepal Health Research Council (NHRC) Ethics Committee + IRB coordination + Nepalese SUSAR reporting via National Pharmacovigilance Centre.
• National Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Nepalese ICSR + Nepal PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting with substantial mountain-geography access support.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + traditional-medicine workflow — DDA frameworks dossier packaging + risk-based classification + ISO 13485 + Nepalese Authorised Representative + post-market vigilance + distinctive Nepalese-traditional Ayurveda + Unani + Amchi/Sowa-Rigpa + Naturopathy traditional-medicine framework + Department of Ayurveda + Alternative Medicine (DoAA) coordination.
• High-altitude Himalayan + earthquake-resilience workflow — substantial Climate Zone I Himalayan high-altitude (above 2500m) stability monitoring + post-2015 Gorkha earthquake reconstruction context + ongoing earthquake-resilience requirements for pharmaceutical-distribution infrastructure + cold-chain packaging.
• Federal-restructuring transition workflow — substantial 2015 Constitution federal restructuring (7 Provinces + 77 Districts + 753 Local Levels) concurrent provincial + local health-jurisdiction packaging.
• Cross-border Indian + Chinese pharmaceutical-trade workflow — substantial open Indo-Nepal border + Rasuwagadhi + Tatopani + Birgunj + Bhairahawa + Kakarbhitta border-crossing complexity packaging.
• Nepalese-domestic manufacturer support workflow — emerging Nepalese-domestic pharmaceutical-manufacturing capacity packaging including technology-transfer + joint-venture opportunities support for ~50+ Nepalese-domestic manufacturers.
• SAARC Secretariat host-country bridging — for companies operating across SAARC + WHO SEARO regional jurisdictions, V5 surfaces DDA + India CDSCO + Bangladesh DGDA + Pakistan DRAP + Sri Lanka NMRA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH + Chinese NMPA harmonised dossier-element reuse alongside national-specific extensions leveraging SAARC Secretariat Kathmandu host-country position.
• GCC migrant-worker healthcare workflow — substantial ~3-5 million Nepalese migrant workers in GCC healthcare-portability + GCC-Nepal pharmaceutical-trade packaging.